Study Condition(s): Solid Tumor, Lung Cancer
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Study Alias: JSCC
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participant must have a diagnosis of cancer (confirmed by histology or cytology) that is not responsive to other treatments
- Participant must be willing to undergo tumor biopsies during the study